Uncover what keeps GLP-1 patients on therapy, and what doesn't
A pharmaceutical manufacturer used HealthVerity Marketplace real-world semaglutide data to analyze GLP-1 medication persistence and adherence. The analysis covered nearly 3.9 million patients over two years, aiming to identify where in the treatment journey patient attrition occurs. By combining closed claims and EHR data, the company quantified persistence rates, pinpointed critical drop-off points, and evaluated clinical outcomes, while noting the difficulty of measuring long-term effectiveness without comprehensive longitudinal data visibility.
The customer is anonymised in HealthVerity’s own case study — not withheld by us.
HealthVerity is a real-world-data marketplace aggregating claims, EHR and lab data from 75+ sources via a proprietary patient-matching layer.
This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.
Published by HealthVerity on its own site — read the original case study on info.healthverity.com ↗
Related use cases
- 01Symphony Health and dentsu health partner to efficiently reach rare disease patients
- 02Differentiating TYK2 inhibitors with real-world evidence in psoriasis
- 03How HealthVerity Audiences delivered 26.9x targeting precision for a rare kidney disease campaign
- 04Reducing targeting noise by supplementing claims with oncology labs: Metastatic breast cancer case study
- 05Accurately targeting chronic liver disease patients for specialty therapy
- 06Accurately reaching patients with rare hematologic disease